

1ST SYMPOSIUM ON INNOVATIVE THERAPIES IN HEMATOLOGY

Avellino, March 30-31, 2023

Hotel de la Ville - Avellino

PROGRAM

March 30, 2023

12:00 – 13:00 Welcome reception

13:00 – 13:30 Opening

C. Gridelli (Avellino), R. Lanzetta (Avellino), R. Pizzuti (Avellino), A.M. Risitano (Avellino)

I SESSION - Novel treatment paradigms in AA, PNH and HES

Chairpersons: A. Bacigalupo (Roma), C. Selleri (Salerno)

13:30 – 14:00 Triple therapy for SAA

C. Dufour (Genova)

14:00 – 14:30 IFN in AA: from the bench to the bedside?

V. Giudice (Salerno)

14:30 – 15:00 Improving terminal complement inhibitors for PNH

R. Notaro (Firenze)

15:00 – 15:30 Proximal complement inhibitors for PNH: a visionary journey

A.M. Risitano (Avellino)

15:30 – 16:00 Targeted treatments for mastocytosis

M. Triggiani (Salerno)

16:00 – 16:30 *Coffee break*

II SESSION - Rare anemias: setting the new standards of care

Chairpersons: C. Dufour (Genova), A.P. Iori (Roma)

16:30 – 17:00 Inherited hemolytic anemias

P. Bianchi (Milano)

17:00 – 17:30 Targeted therapies for AIHA and CAD

W. Barcellini (Milano)

17:30 – 18:00 New treatment options for sickle cell disease

L. De Franceschi (Verona)

18:00 – 18:30 Luspatercet for thalassemias and ineffective erythropoiesis anemias

M.D. Cappellini (Milano)

18:30 – 19:00 Congenital dyserythropoietic anemias

A. Iolascon (Napoli)

March 31, 2023

III SESSION - Gene therapy and CAR-T strategies

Chairpersons: A.M. Risitano (Avellino), A. Raiola (Genova)

08:30 – 09:00 Genes and gene therapies

L. Luzzatto (Dar es Salaam – TZ)

09:00 – 09:30 Gene manipulation for advancing GMP manufacturing of CAR-T cells (and of other gene therapies)

C. Quintarelli (Roma)

09:30 – 10:00 Gene therapies for hemoglobinopathies

F. Locatelli (Roma)

10:00 – 10:30 CAR-T for NHL

B. Casadei (Bologna)

10:30 – 11:00 Allogeneic CAR-T: where we are and where we are going

F. Ciceri (Milano)

11:00 – 11:30 *Coffee break*

IV SESSION - Developing innovative treatments for other hematological malignancies

Chairpersons: B. Bruno (Torino), G. Storti (Avellino)

11:30 – 12:00 Targeted therapies for AML: flt-3 and beyond

F. Ferrara (Napoli)

12:00 – 12:30 CAR-T and other innovative treatments for ALL

A. Rambaldi (Bergamo)

12:30 – 13:00 ADC vs CAR-T vs bispecific antibodies for MM

M. Rossi (Catanzaro)

13:00 – 13:30 Overcoming the HLA barrier in transplantation: PTCY revolution

A. Bacigalupo (Roma)

13:30 – 14:00 Ruxolitinib and other innovative treatments for GVHD

M.T. Lupo-Stanghellini (Milano)

14:00 – 15:00 *Lunch*

V SESSION - Platelet, hemostasis and thrombosis

Chairpersons: G. Di Minno (Napoli), E. Di Bona (Bassano)

15:00 – 15:30 Future treatment options for ITP: does one fit all?

M. Carpenedo (Monza-MB)

15:30 – 16:00 Thrombotic risk and its management in myeloproliferative neoplasms

A. Volpe (Avellino)

16:00 – 16:30 Changing the treatment paradigm of TTP: caplacizumab

B. Ferrari (Milano)

16:30 – 17:00 New treatment options for hemophilias

G. Di Minno (Napoli)

17:00 – 17:30 Acquired hemophilias: what's new?

A. Ciampa (Avellino)

17:30 – 18:00 Conclusion and take-home messages

A.M. Risitano (Avellino)